Bengaluru: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of
Biocon Ltd, has announced a settlement and license
agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf),
an interchangeable biosimilar aflibercept, in the United States.YESAFILI, a vascular
endothelial growth factor (VEGF) inhibitor, is used to treat several different types of
ophthalmology conditions, is a biosimilar of its reference product EYLEA (aflibercept).
Biocon Biologics and Regeneron executed the settlement agreement to dismiss the pending
appeal at the United States Court of Appeals for the Federal Circuit (USCAFC) of patent
US11084865 (‘865 patent) and the pending litigation at the U.S. District Court for the
Northern District of West Virginia, Clarksburg Division.
This agreement enables the Company to launch in the United States in the second half of
calendar year 2026 or earlier in certain circumstances. The terms of the settlement are
confidential.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics Ltd., said, “This settlement
clears the path for Biocon Biologics to be among the first to bring a reliable, high-quality
aflibercept biosimilar to patients and healthcare providers in the United States. As the first to-file interchangeable biosimilar to Eylea, YESAFILI affirms our scientific strength and
marks our strategic entry into Ophthalmology, expanding our footprint in the U.S. and
advancing our mission to increase access to life-changing treatments.”
Previously, the U.S. Food and Drug Administration (U.S. FDA) approved Yesafili (afliberceptjbvf), an interchangeable biosimilar aflibercept in May 2024. Additionally, Biocon Biologics
secured a settlement agreement in Canada with Bayer Inc. and Regeneron Pharmaceuticals,
Inc., for the launch of YESAFILI no later than July 1, 2025.
YESAFILI is intended for the treatment of neovascular (wet AMD) age-related macular
degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion
(branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and
visual impairment due to myopic choroidal neovascularisation (myopic CNV). It is highly
similar to the reference product Eylea (aflibercept). Data shows that YESAFILI has
comparable quality, safety, and efficacy to Eylea.